) is a device designed to add nitric oxide to a ventilator breathing system so that the inspired nitric oxide concentration remains constant in spite of changes in minute ventilation. In a laboratory study the device maintained the inspired nitric oxide concentration delivered to a model lung in the range 10.2-10.7 parts per million (ppm) when set to deliver 10 ppm, and in the range 40.5-42 ppm when set to deliver 40 ppm, for tidal volumes of 500, 700 and 900 ml, ventilator rates of 10, 15 and 20 bpm, peak inspiratory flow rates of 30, 40 and 50 litre min
Inhaled nitric oxide is used increasingly to treat hypoxaemia and pulmonary hypertension associated with acute respiratory failure. Most centres in the UK use systems where a continuous flow of nitric oxide-nitrogen mixture is introduced into the inspiratory limb of the ventilator system, but this results in uneven nitric oxide concentrations being delivered during inspiration, and the inspired concentration changes when the patient's minute volume changes. There are only a few systems available for mixing nitric oxide with the inspired gas delivered by a ventilator which maintain a fixed inspired nitric oxide concentration in the face of varying minute ventilation. Two systems are available which only function with specific ventilators, the Nomius "C" for Siemens Servo 900 series ventilators, and the NODomo, for Dräger ventilators. True universal nitric oxide delivery systems, which can work with a range of ventilators or anaesthetic machines to deliver a fixed concentration of nitric oxide independent of minute ventilation or fresh gas flow, have not been available commercially. While we were constructing a prototype device 1 based on a fast-responding mass flow controller, we were aware that Ohmeda were independently developing a more sophisticated device (I-NOvent delivery system) using a similar principle. We report a bench test of the preproduction UK specification prototype of this device.
Description of the I-NOvent delivery system
The I-NOvent delivery system is shown in figure 1 and a diagram of the system is presented in figure 2 . The device is mounted on a wheeled plinth which also acts as a carrier for two 10-litre nitric oxide-nitrogen mixture cylinders. Two regulators to reduce cylinder pressure to a lower working pressure are built into the plinth, together with two cylinder pressure (contents) gauges. The device measures inspiratory gas flow with a hot film anemometer placed in the inspiratory limb of the breathing system and delivers the appropriate flow of nitric oxide-nitrogen mixture (1000 ppm of nitric oxide in nitrogen) downstream of the flow sensor with an injector port integral to the sensor housing. The flow of the nitric oxide-nitrogen mixture is controlled with two proportional solenoid valves and monitored with hot film anemometers, effectively forming two mass flow controllers. Mass flow controllers are devices which control the mass rather than the velocity or volume of gas flowing through them. They are not affected by fluctuations in supply or downstream pressures. The mass of gas passing through can be controlled with an electrical signal. The inspired gas is sampled in the inspiratory limb of the ventilator system approximately 20 cm upstream from the Y piece of the system, and drawn through a water trap before being analysed for nitric oxide, nitrogen dioxide and oxygen concentrations by two electrochemical cells and a fuel cell, respectively. These sensors are for monitoring only, and do not have any effect on the control of nitric oxide delivery.
The front panel contains an electroluminescent screen on which measured inspired nitric oxide, nitrogen dioxide and oxygen concentrations are displayed. The set nitric oxide concentration is also displayed, together with any alarm messages. Calibration, alarms, delivered nitric oxide concentration and display brightness are controlled by seven multifunction push buttons and a single combined rotary/push switch control. The device can deliver nitric oxide 0-80 ppm at ventilator peak inspiratory flow rates below 55 litre min -1 and 0-50 ppm at ventilator peak inspiratory flow rates of 55-120 litre min -1 . To allow nitric oxide to be delivered during manual ventilation the device is designed to be fitted with an external oxygen flowmeter, valve and inlet hose. If oxygen is turned on at 15 litre min -1 , nitric oxide is added to give a final concentration of 10 ppm. The oxygen-nitric oxide mixture then passes to an outlet which can be connected to a manual ventilation system. The manual system is totally pneumatic and independent of the primary system, and operates even if all power is lost to the device. A battery provides 30 min of backup power. ). A sampling port was fitted to the test lung, which allowed the concentration of nitric oxide to be measured using an Eco Physics CLD 700AL chemiluminescence analyser (Eco Physics, Dürnten, Switzerland). The flow sensor for the I-NOvent delivery system was placed in the inspiratory limb of the breathing system after the inspiratory filter, the sampling port was placed in the inspiratory limb 20 cm upstream from the "Y" piece. Flow into and out of the test lung was measured using a TUBA ultrasonic flow measuring device (Transit-time Ultrasonic Breath Analyser, GHG Medical Electronics GMBH, Zürich, Switzerland) 2 and flow of the nitric oxide-nitrogen mixture from the I-NOvent delivery system was measured by inserting a locally made screen pneumotachograph into the delivery tube. Pressure changes across the pneumotachograph were measured using a Validyne 2-0-2 cm H 2 O (0.2-0-0.2 kPa) pressure transducer/amplifier (Validyne Engineering Co, Northridege, CA, USA). Flow signals were recorded at 500 samples s 91 using locally written software running on a Viglen 386 personal computer (Viglen Ltd, Alperton, UK) and an AT-M10-16 analogueto-digital converter (National Instruments Ltd, Newbury, UK).
Test procedure
The sequence of ventilator settings was the same as we used previously 1 ; in all cases 50% oxygen was used. The tests were performed at nitric oxide settings of 10 and 40 ppm. The ventilator was then set at 10 bpm, peak flow 40 litre min -1 , tidal volume 700 ml, square wave profile, and the device tested with nitric oxide settings of 1, 5, 10, 20, 40, 60 and 80 ppm, which are the marked concentrations on the bar indicator that is used to set the nitric oxide concentration.
The integral sensors were calibrated according to the manufacturer's instructions using air as zero for nitric oxide and nitrogen dioxide and 21% standard for oxygen, and nitric oxide 81.5 ppm in nitrogen, nitrogen dioxide 10.4 ppm in nitrogen and 100% oxygen, respectively, as span gases. The calibration gases were supplied by the manufacturer. The chemiluminescence analyser was calibrated using a separate nitric oxide 5.0 ppm standard and checked with the 81.5 ppm standard. The chemiluminescence analyser (in the mode used) has British Journal of Anaesthesia a display resolution of 0.01 ppm, but the results are given to the nearest 0.1 ppm for the 10-ppm tests and 0.5 ppm for the 40-ppm tests as the standard gas mixes against which the analyser was calibrated are prepared to 2% accuracy. The flow sensor for the nitric oxide mixture was tested for linearity and calibrated using a Timeter RT-200 (SLE Ltd, South Croydon, UK) as the standard, and 100% nitrogen as the test gas. The TUBA is self-calibrating, and corrects automatically for gas composition. Nitrogen dioxide concentrations were not recorded from the CLD 700AL because calibration standards have to be prepared in the same gas mixture as the measured gas, and it was not possible to do this accurately.
Results
A total of 42 different combinations of ventilator and nitric oxide settings were tested (table 1). Table 2 shows the results of the linearity test at nitric oxide concentrations of 1-80 ppm. Figures 3 and 4 show the ventilator flow waveforms and the nitric oxide flow waveforms, for the three different inspiratory waveforms tested and for nitric oxide concentrations of 10 and 40 ppm. As the ventilator and device valves opened and closed, transient spikes were observed on the nitric oxide-nitrogen flow trace, probably caused by the poor frequency response of the pneumotachograph. To partially remove these the nitric oxide-nitrogen flow traces were smoothed with a 41-point running average from the time the valve opened or closed to 80 ms later. The traces are otherwise unaltered.
Discussion
The device appeared to function very well. Control of inspired nitric oxide concentration over a wide range of ventilator settings was excellent, and more precise than is required in clinical use. Its ability to maintain constant nitric oxide concentrations over a range of settings was related presumably to the close matching of the ventilator and nitric oxide-nitrogen flow profiles, which were apparent on the flow traces. To achieve this the flow control devices (and their associated electronics) must have a very fast response time. Although we did not formally measure the response time of the device, the speed of response can be seen clearly on the flow traces at the start of inspiration, when the ventilator flow is changing rapidly. There was virtually no delay in the response of the delivery device. The built-in nitric oxide meter consistently read lower than the chemiluminescence analyser except at 1 ppm, in spite of correct calibration, but the errors were small and not clinically important. In addition, the resolution of the electrochemical cells was only 1-2 ppm (3% of full scale), so the errors were within the expected range.
The limitations of these tests should be noted. They were conducted at a series of ventilator settings covering commonly used inspiratory flow rates, tidal volumes, rates and waveforms. However, we did not test the extremes of the ventilator capability (for example, the Puritan Bennett 7200 can deliver peak inspiratory flow rates of up to 120 litre min 91 ), nor did we test the device in any patient-triggered mode (i.e. pressure support). We did not test the device with any continuous-flow ventilators or modes of ventilation, or paediatric ventilators. The absolute accuracy of any measured gas concentrations depends on the standards used, in this case they were within 2% of the nominal concentration.
The technology developed for this device may have other applications in respiratory physiology and experimental medicine. Sulphur hexafluoride injection into the inspiratory gas flow has been used to measure functional residual capacity, and sinusoidally varying concentrations of tracer gases added to the inspiratory gas flow can be used to determine deadspace, alveolar volume and pulmonary blood flow. 3 Until now it was very difficult to perform these measurements in patients undergoing ventilation because reliably adding and mixing tracer gases into the inspired gas is technically challenging. These techniques require careful matching of tracer gas flow to inspired gas flow, which is what this device is designed to do. Continuous measurement of lung volumes and pulmonary blood flow in patients undergoing artificial ventilation may be a useful spin-off from this project.
